<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Frutiger-UltraBlack,Bold" color="#4e67ad"/>
	<fontspec id="font1" size="9" family="Frutiger-UltraBlack,Bold" color="#007682"/>
	<fontspec id="font2" size="9" family="Courier" color="#007682"/>
	<fontspec id="font3" size="9" family="Frutiger-Light" color="#000000"/>
	<fontspec id="font4" size="9" family="ArialMT" color="#000000"/>
	<fontspec id="font5" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font6" size="20" family="Frutiger-UltraBlack,Bold" color="#000000"/>
	<fontspec id="font7" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font8" size="14" family="GillSans-Light" color="#000000"/>
	<fontspec id="font9" size="16" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font10" size="15" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font11" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font12" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font13" size="10" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font14" size="10" family="GillSans" color="#000000"/>
	<fontspec id="font15" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font16" size="8" family="GillSans" color="#000000"/>
	<fontspec id="font17" size="8" family="GillSans,Italic" color="#000000"/>
	<fontspec id="font18" size="8" family="GillSans,Bold" color="#000000"/>
<text top="44" left="508" width="16" height="9" font="font0" id="p1_t1" reading_order_no="2" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/"><b>Bio</b></a></text>
<text top="44" left="525" width="22" height="9" font="font1" id="p1_t2" reading_order_no="3" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/"><b>Med</b></a></text>
<text top="44" left="548" width="27" height="9" font="font3" id="p1_t3" reading_order_no="4" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/">Central</a></text>
<text top="756" left="508" width="46" height="10" font="font4" id="p1_t4" reading_order_no="71" segment_no="25" tag_type="text">Page 1 of 6</text>
<text top="769" left="432" width="122" height="8" font="font5" id="p1_t5" reading_order_no="72" segment_no="26" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="19" left="55" width="376" height="19" font="font6" id="p1_t6" reading_order_no="0" segment_no="0" tag_type="title"><b>Journal of Occupational Medicine </b></text>
<text top="39" left="55" width="169" height="19" font="font6" id="p1_t7" reading_order_no="1" segment_no="0" tag_type="title"><b>and Toxicology</b></text>
<text top="86" left="502" width="79" height="10" font="font7" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="title"><a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="87" left="55" width="61" height="13" font="font8" id="p1_t9" reading_order_no="6" segment_no="3" tag_type="title">Hypothesis</text>
<text top="105" left="55" width="430" height="15" font="font9" id="p1_t10" reading_order_no="7" segment_no="4" tag_type="title"><b>Supplement use in sport: is there a potentially dangerous </b></text>
<text top="123" left="55" width="343" height="15" font="font9" id="p1_t11" reading_order_no="8" segment_no="4" tag_type="title"><b>incongruence between rationale and practice?</b></text>
<text top="140" left="55" width="271" height="14" font="font10" id="p1_t12" reading_order_no="9" segment_no="5" tag_type="text">Andrea Petróczi* and Declan P Naughton</text>
<text top="176" left="55" width="392" height="8" font="font11" id="p1_t13" reading_order_no="10" segment_no="6" tag_type="text">Address: School of Life Sciences, Kingston University, Penrhyn Road, Kingston upon Thames, Surrey KT1 2EE, UK</text>
<text top="190" left="55" width="363" height="8" font="font11" id="p1_t14" reading_order_no="11" segment_no="7" tag_type="text">Email: Andrea Petróczi* - A.Petroczi@kingston.ac.uk; Declan P Naughton - D.Naughton@kingston.ac.uk</text>
<text top="202" left="55" width="92" height="8" font="font11" id="p1_t15" reading_order_no="12" segment_no="8" tag_type="text">* Corresponding author  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17535442">  </a></text>
<text top="350" left="112" width="44" height="10" font="font12" id="p1_t16" reading_order_no="25" segment_no="16" tag_type="title"><b>Abstract</b></text>
<text top="365" left="112" width="60" height="9" font="font13" id="p1_t17" reading_order_no="26" segment_no="17" tag_type="text"><b>Background: </b></text>
<text top="365" left="172" width="325" height="9" font="font14" id="p1_t18" reading_order_no="27" segment_no="17" tag_type="text">Supplement use by athletes is complex and research supports the alarming notion</text>
<text top="376" left="112" width="192" height="9" font="font14" id="p1_t19" reading_order_no="28" segment_no="17" tag_type="text">of misinformed decisions regarding supplements.</text>
<text top="393" left="112" width="56" height="9" font="font13" id="p1_t20" reading_order_no="29" segment_no="18" tag_type="text"><b>Hypothesis: </b></text>
<text top="393" left="168" width="330" height="9" font="font14" id="p1_t21" reading_order_no="30" segment_no="18" tag_type="text">A frequent divergence between the type of supplements chosen by athletes and the</text>
<text top="405" left="112" width="386" height="9" font="font14" id="p1_t22" reading_order_no="31" segment_no="18" tag_type="text">rationale dictating the supplement use is hypothesized. Thus, a potentially dangerous incongruence</text>
<text top="417" left="112" width="164" height="9" font="font14" id="p1_t23" reading_order_no="32" segment_no="18" tag_type="text">may exist between rationale and practice.</text>
<text top="433" left="112" width="114" height="9" font="font13" id="p1_t24" reading_order_no="33" segment_no="19" tag_type="text"><b>Testing the hypothesis: </b></text>
<text top="433" left="226" width="271" height="9" font="font14" id="p1_t25" reading_order_no="34" segment_no="19" tag_type="text">In the continued absence of reliable data on supplement use, an</text>
<text top="445" left="112" width="386" height="9" font="font14" id="p1_t26" reading_order_no="35" segment_no="19" tag_type="text">alternative approach of studying the reasons underlying supplement use in athletes is proposed to</text>
<text top="457" left="112" width="386" height="9" font="font14" id="p1_t27" reading_order_no="36" segment_no="19" tag_type="text">determine whether there is an incongruence between rationale and practice. Existing data from</text>
<text top="469" left="112" width="285" height="9" font="font14" id="p1_t28" reading_order_no="37" segment_no="19" tag_type="text">large scale national surveys can be used to investigate this incongruence.</text>
<text top="485" left="112" width="141" height="9" font="font13" id="p1_t29" reading_order_no="38" segment_no="20" tag_type="text"><b>Implications of the hypothesis: </b></text>
<text top="485" left="253" width="245" height="9" font="font14" id="p1_t30" reading_order_no="39" segment_no="20" tag_type="text">In this report, analyses of distinctive patterns between the use</text>
<text top="497" left="112" width="385" height="9" font="font14" id="p1_t31" reading_order_no="40" segment_no="20" tag_type="text">and rationale for use of supplements among athletes are recommended to explore this potentially</text>
<text top="509" left="112" width="97" height="9" font="font14" id="p1_t32" reading_order_no="41" segment_no="20" tag_type="text">dangerous phenomenon.</text>
<text top="558" left="55" width="60" height="10" font="font12" id="p1_t33" reading_order_no="42" segment_no="21" tag_type="title"><b>Background</b></text>
<text top="570" left="55" width="241" height="9" font="font15" id="p1_t34" reading_order_no="43" segment_no="23" tag_type="text">'Supplement' is an overarching name for vitamins, miner-</text>
<text top="581" left="55" width="241" height="9" font="font15" id="p1_t35" reading_order_no="44" segment_no="23" tag_type="text">als, herbal remedies, traditional Asian remedies, amino</text>
<text top="593" left="55" width="241" height="9" font="font15" id="p1_t36" reading_order_no="45" segment_no="23" tag_type="text">acids and other substances to be taken orally. They may</text>
<text top="605" left="55" width="241" height="9" font="font15" id="p1_t37" reading_order_no="46" segment_no="23" tag_type="text">also be referred to as dietary, food or nutritional supple-</text>
<text top="617" left="55" width="241" height="9" font="font15" id="p1_t38" reading_order_no="47" segment_no="23" tag_type="text">ments or ergogenic aids (supplements purported to</text>
<text top="629" left="55" width="241" height="9" font="font15" id="p1_t39" reading_order_no="48" segment_no="23" tag_type="text">improve athletic performance) and are typically sold in</text>
<text top="640" left="55" width="241" height="9" font="font15" id="p1_t40" reading_order_no="49" segment_no="23" tag_type="text">the form of tablets, capsules, soft gels, liquids, powders,</text>
<text top="652" left="55" width="241" height="9" font="font15" id="p1_t41" reading_order_no="50" segment_no="23" tag_type="text">and bars. In the UK, most supplements are regulated as</text>
<text top="664" left="55" width="241" height="9" font="font15" id="p1_t42" reading_order_no="51" segment_no="23" tag_type="text">foods and subject to the general provisions of the Food</text>
<text top="676" left="55" width="241" height="9" font="font15" id="p1_t43" reading_order_no="52" segment_no="23" tag_type="text">Safety Act 1990, the Food Labelling Regulations 1996 and</text>
<text top="687" left="55" width="241" height="9" font="font15" id="p1_t44" reading_order_no="53" segment_no="23" tag_type="text">the Trade Descriptions Act 1968. Supplements are not</text>
<text top="699" left="55" width="241" height="9" font="font15" id="p1_t45" reading_order_no="54" segment_no="23" tag_type="text">required to exhibit efficacy before marketing, nor are they</text>
<text top="711" left="55" width="241" height="9" font="font15" id="p1_t46" reading_order_no="55" segment_no="23" tag_type="text">subject to prior approval unless they are genetically mod-</text>
<text top="722" left="55" width="241" height="9" font="font15" id="p1_t47" reading_order_no="56" segment_no="23" tag_type="text">ified or claimed to be new. Medicinal claims on packaging</text>
<text top="558" left="313" width="241" height="9" font="font15" id="p1_t48" reading_order_no="57" segment_no="22" tag_type="text">or in an advertisement for a supplement, however, are</text>
<text top="570" left="313" width="47" height="9" font="font15" id="p1_t49" reading_order_no="58" segment_no="22" tag_type="text">prohibited.</text>
<text top="593" left="313" width="241" height="9" font="font15" id="p1_t50" reading_order_no="59" segment_no="24" tag_type="text">Widespread debate has accompanied the introduction of</text>
<text top="605" left="313" width="241" height="9" font="font15" id="p1_t51" reading_order_no="60" segment_no="24" tag_type="text">new legislation on the use of dietary supplements within</text>
<text top="617" left="313" width="241" height="9" font="font15" id="p1_t52" reading_order_no="61" segment_no="24" tag_type="text">the EU. Comprehension of detailed studies, ranging from</text>
<text top="629" left="313" width="241" height="9" font="font15" id="p1_t53" reading_order_no="62" segment_no="24" tag_type="text">quantities and patterns of use to side-effects of supple-</text>
<text top="640" left="313" width="241" height="9" font="font15" id="p1_t54" reading_order_no="63" segment_no="24" tag_type="text">ment consumption, has been impeded by variations in</text>
<text top="652" left="313" width="241" height="9" font="font15" id="p1_t55" reading_order_no="64" segment_no="24" tag_type="text">terminology and practice amongst countries and user</text>
<text top="664" left="313" width="241" height="9" font="font15" id="p1_t56" reading_order_no="65" segment_no="24" tag_type="text">groups. Some thirty thousand supplements are commer-</text>
<text top="676" left="313" width="241" height="9" font="font15" id="p1_t57" reading_order_no="66" segment_no="24" tag_type="text">cially-available <a href="">in the USA [1] with approx</a>imately half of</text>
<text top="687" left="313" width="241" height="9" font="font15" id="p1_t58" reading_order_no="67" segment_no="24" tag_type="text">the adult female population being regular user<a href="">s [2-4],</a></text>
<text top="699" left="313" width="241" height="9" font="font15" id="p1_t59" reading_order_no="68" segment_no="24" tag_type="text">with possible adverse effects of unregulated supplement</text>
<text top="711" left="313" width="241" height="9" font="font15" id="p1_t60" reading_order_no="69" segment_no="24" tag_type="text">use on health and disease outcomes being of particular</text>
<text top="722" left="313" width="48" height="9" font="font15" id="p1_t61" reading_order_no="70" segment_no="24" tag_type="text">intere<a href="">st [1].</a></text>
<text top="244" left="55" width="76" height="7" font="font16" id="p1_t62" reading_order_no="13" segment_no="9" tag_type="text">Published: 29 May 2007</text>
<text top="259" left="55" width="146" height="7" font="font17" id="p1_t63" reading_order_no="14" segment_no="12" tag_type="text"><i>Journal of Occupational Medicine and Toxicology</i></text>
<text top="259" left="201" width="22" height="7" font="font16" id="p1_t64" reading_order_no="15" segment_no="12" tag_type="text"> 2007, </text>
<text top="259" left="223" width="4" height="7" font="font18" id="p1_t65" reading_order_no="16" segment_no="12" tag_type="text"><b>2</b></text>
<text top="259" left="228" width="6" height="7" font="font16" id="p1_t66" reading_order_no="17" segment_no="12" tag_type="text">:4</text>
<text top="259" left="242" width="88" height="7" font="font16" id="p1_t67" reading_order_no="18" segment_no="12" tag_type="text">doi:10.1186/1745-6673-2-4</text>
<text top="244" left="349" width="85" height="7" font="font16" id="p1_t68" reading_order_no="23" segment_no="10" tag_type="text">Received: 30 January 2007</text>
<text top="254" left="349" width="76" height="7" font="font16" id="p1_t69" reading_order_no="24" segment_no="11" tag_type="text">Accepted: 29 May 2007</text>
<text top="273" left="55" width="231" height="7" font="font16" id="p1_t70" reading_order_no="19" segment_no="13" tag_type="text"><a href="http://www.occup-med.com/content/2/1/4">This article is available from: http://www.occup-med.com/content/2/1/4</a></text>
<text top="287" left="55" width="201" height="7" font="font16" id="p1_t71" reading_order_no="20" segment_no="14" tag_type="text">© 2007 Petróczi and Naughton; licensee BioMed Central Ltd. </text>
<text top="297" left="55" width="492" height="7" font="font16" id="p1_t72" reading_order_no="21" segment_no="15" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution Licens<a href="http://creativecommons.org/licenses/by/2.0">e (http://creativecommons.org/licenses/by/2.0), </a></text>
<text top="306" left="55" width="400" height="7" font="font16" id="p1_t73" reading_order_no="22" segment_no="15" tag_type="text">which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
</page>
</pdf2xml>
